Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
Australia
Clinical Study Center, Adelaide Clinical Study Center, Melbourne Canada
Clinical Study Center, Chicoutimi Clinical Study Center, Montreal Clinical Study Center, Toronto South Africa
Clinical Study Center, Cape Town Clinical Study Center, Johannesburg United Kingdom
Clinical Study Center, Liverpool Clinical Study Center, London Clinical Study Center, Manchester